Analyst’s ‘Top Pick’ Advances Vaccine Candidates

Source: Streetwise Reports   11/21/2017 Douglas Loe, an analyst with Echelon Wealth Partners, provided an update on this biotech’s platform pipeline targeting ovarian and blood cancers, as well as respiratory syncytial virus. . . . → Read More: Analyst’s ‘Top Pick’ Advances Vaccine Candidates Similar Articles: Biotech with Solid Pipeline and ‘Solid Partnership Outlook’ Analysts Take Note as Small-Cap Biotech Completes Early Enrollment for Phase 3 Trial HIV Vaccine Clinical Study Results in High Immune Response Rates in Healthy Subjects